



These additions apply to Exchange formularies and are effective 4/14/23.

Additions:

Relyvrio (sodium phenylbutyrate and taurursodiol)– Pharmacy Benefit, Non-Preferred brand, PA and QL of 2 packets per day.

Sunlenca (lenacapavir) – Pharmacy Benefit, Non-Preferred brand, QL of 5 per 30 for 300mg tablet and 1.5ml per 6 months for injection.

Krazati (adagrasib) – Pharmacy Benefit, Non-Preferred brand, PA and QL of 2 per day.

Rezlidhia (olutasidenib) – Pharmacy Benefit, Non-Preferred brand, PA and QL of 2 per day.

Lytgobi (futibatinib) – Pharmacy Benefit, Non-Preferred brand, PA and QL of 5 per day.

Tzielid (teplizumab-mzwv) – Medical Benefit, PA

Elahere (mirvetuximab soravtansine-gynx) – Medical Benefit, PA

Tecvayli (teclistamab-cqyv) – Medical Benefit, PA

Imjudo (tremelimumab-actl) – Medical Benefit, PA

Rolvedon (eflapegastim-xnst) – Medical Benefit, PA